What sample amount is required for a full characterization panel?

Sample requirements depend on the techniques selected. Typically 1–2 mL of liquid nanoformulation or 10–20 mg of solid is sufficient for the core panel. Exact quantities are confirmed during project scoping to avoid sample wastage.

Can you analyze lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles?

Yes. Our analytical platforms accommodate a wide range of nanoformulations, including liposomes, LNPs, PLGA/PLA carriers, albumin nanoparticles, and metal/oxide nanoparticles. Protocols are adapted to the specific material and solvent system.

Do you provide in vitro release studies under biorelevant conditions?

We perform release studies using dialysis or reverse dialysis methods in buffers simulating physiological pH and ionic strength. Conditions such as enzyme presence or serum can be incorporated when needed. Release kinetics are fitted to multiple models for mechanistic insight.

How do you ensure data reproducibility across batches?

Our workflows incorporate standard operating procedures, instrument calibration checks, and replicate measurements where feasible. We provide batch-to-batch comparability data and statistical analysis as part of the deliverable.

Can you support regulatory submissions with the characterization data?

Our reports are designed to be suitable for IND/CTA sections. We can bridge to ICH guidelines, provide method validation summaries, and supply raw data upon request. Specific regulatory requirements are discussed during project scoping.

What is the typical turnaround for a characterization project?

Turnaround time is project-dependent and confirmed at scoping. Routine physicochemical parameters are typically reported within a few weeks, while detailed release kinetics and stability studies require longer timelines. Please contact us for a project-specific estimate.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Nanoformulation Characterization & Release Kinetics Analysis

Nanoformulation Characterization

Comprehensive physicochemical profiling and drug release kinetics for optimizing nanoformulation stability and therapeutic performance.

Particle size and size distribution via DLS, NTA, and laser diffraction
Surface charge (zeta potential) measurement for colloidal stability assessment
Morphology and structural integrity imaging by cryo-TEM and SEM
Chemical composition and purity analyzed by FTIR, Raman, ICP-MS
In vitro drug release profiling with kinetic model fitting

Request Consultation

Why Comprehensive Characterization Matters

Accurate nanoformulation characterization ensures predictive performance, batch consistency, and regulatory readiness.

Identifies formulation variables affecting size, charge, and encapsulation
Detects aggregation, degradation, and structural defects early
Supports IND/CTA regulatory submissions with validated data
Enables batch-to-batch comparability and scale-up confidence
Reveals release mechanisms for informed formulation design

Reproducible

Regulatory-Ready

Methodical

Our Methodology

Integrated Characterization & Release Analysis

We combine orthogonal analytical techniques to deliver a complete understanding of your nanoformulation's physical, chemical, and release behavior.

Core Analytical Pipeline

A multi-technique approach covering size, charge, morphology, and composition to build a holistic profile of your formulation.

Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) for size and distribution
Cryo-TEM and SEM for morphology, membrane integrity, and aggregation assessment
Zeta potential measurement across relevant pH/ionic strength conditions
Chemical composition via FTIR, Raman, EDS, and ICP-MS for purity and functionalization verification

Drug Release Kinetics Profiling

In vitro release studies under simulated physiological conditions to model release kinetics and guide formulation refinement.

Dialysis and reverse dialysis methods for sink-condition release testing
Release media optimization to match intended biological environment
Kinetic model fitting: zero-order, first-order, Higuchi, and Korsmeyer-Peppas
Payload stability and drug-loading efficiency determination

Quality & Reproducibility

All assays are run with validated protocols, instrument calibration, and batch controls to ensure reliable, comparable results across runs.

Statistical Rigor

Data analysis incorporates error propagation, model selection criteria (AIC), and replicate measurements for confidence in reported parameters.

Biological Interpretability

Our reports place physicochemical results in the context of in vivo performance, helping teams predict bioavailability and therapeutic efficacy.

Deliverables

Data, Reports & Regulatory Support

You receive a comprehensive data package with analytical reports and raw data suitable for internal decision-making and regulatory submissions.

Data Deliverables

Raw data files: DLS correlation, NTA videos, TEM images, spectroscopic scans
Processed results: size distribution, zeta potential, encapsulation efficiency, release profiles
Statistical analysis and kinetic model fits with goodness-of-fit metrics
Batch-to-batch comparability data when multiple samples are provided

Reporting & Support

Interpretive report with expert commentary on formulation implications
Graphical summaries suitable for presentations and publications
Method validation documentation as needed for regulatory dossiers
Consultation session to discuss findings and next formulation steps

Service Scope

Tailored Characterization Parameters

Every project is scoped individually to match your nanoformulation type, development stage, and specific analytical questions.

Parameter	Typical Project Scope
Particle Size & Distribution	DLS + NTA; cryo-TEM or SEM for visual confirmation; laser diffraction for broad-range samples
Surface Charge (Zeta Potential)	Electrophoretic light scattering at multiple pH/ionic strength conditions; stability prediction
Morphology & Structure	Cryo-TEM, SEM, AFM as needed; assessment of shape, membrane integrity, and defects
Chemical Composition & Purity	FTIR, Raman, EDS, ICP-MS; identification of excipients, impurities, and functional groups
Encapsulation Efficiency & Drug Loading	Ultrafiltration/centrifugation separation; HPLC or UV quantification of free vs. encapsulated drug
Drug Release Kinetics	Dialysis, reverse dialysis, or Franz cell; release media at physiological pH; model fitting (zero-order, first-order, Higuchi, Korsmeyer-Peppas)
Stability Assessment	Accelerated, freeze-thaw, mechanical stress, and long-term storage; periodic monitoring of size, charge, and payload
Residual Solvent & Impurity Analysis	GC-FID, GC-MS, or LC-MS as required; endotoxin and bioburden testing upon request

Workflow

From Sample to Insight

A streamlined process ensuring quality and transparency at every step, from sample receipt to final report.

Project Scoping & Sample Preparation

We collaborate with your team to define analytical goals, select techniques tailored to your formulation, and prepare samples under controlled conditions to ensure integrity.

Physicochemical Characterization

Core parameters—size, zeta potential, morphology, and composition—are measured using validated instrumentation and standard protocols with appropriate controls.

Drug Release Profiling

In vitro release studies are conducted under physiologically relevant conditions, with timed sampling and quantification to generate release curves.

Data Analysis & Kinetic Modeling

Raw data is processed, release curves are fitted to multiple mathematical models, and statistical analysis is performed to extract kinetic parameters and select the best-fit model.

Reporting & Consultation

A comprehensive report with interpreted results, graphics, and actionable recommendations is delivered, followed by a consultation to discuss findings and next steps.

Applications

Supporting Every Stage of Nanoformulation Development

Our characterization services inform formulation optimization, stability testing, and regulatory filings across therapeutic areas.

Optimize Composition and Process

Understand how formulation variables affect particle size, loading, and release to accelerate candidate selection and reduce development risk.

Screen excipients and process parameters (e.g., homogenization pressure, lipid composition)
Identify optimal drug-to-polymer ratios for target release profile
Reduce batch failure by early detection of instability or poor encapsulation

Ensure Product Robustness

Evaluate physical and chemical stability under real-world and accelerated stress conditions to guide formulation and packaging decisions.

Accelerated stability at elevated temperatures and humidity
Freeze-thaw cycle resistance and mechanical agitation tolerance
Monitoring of size drift, charge change, and payload degradation over time

Deliver Regulatory-Ready Data

Provide characterization data that meets IND/CTA and global regulatory expectations, with method validation and batch comparability documentation.

Method validation per ICH Q2(R1) guidance
Batch-to-batch comparability studies for process consistency
Impurity and residual solvent screening for safety assessment

Understand Drug Release Behavior

Determine release kinetics and mechanisms to predict in vivo performance and support IVIVC model development.

Model fitting: zero-order, first-order, Higuchi, and Korsmeyer-Peppas
Identify diffusion, erosion, or swelling-controlled release
Correlate in vitro release with in vivo absorption where feasible

FAQ

Common Questions About Nanoformulation Characterization

Answers to typical inquiries about our service scope, methods, and deliverables.

Sample requirements depend on the techniques selected. Typically 1–2 mL of liquid nanoformulation or 10–20 mg of solid is sufficient for the core panel. Exact quantities are confirmed during project scoping to avoid sample wastage.
Yes. Our analytical platforms accommodate a wide range of nanoformulations, including liposomes, LNPs, PLGA/PLA carriers, albumin nanoparticles, and metal/oxide nanoparticles. Protocols are adapted to the specific material and solvent system.
We perform release studies using dialysis or reverse dialysis methods in buffers simulating physiological pH and ionic strength. Conditions such as enzyme presence or serum can be incorporated when needed. Release kinetics are fitted to multiple models for mechanistic insight.
Our workflows incorporate standard operating procedures, instrument calibration checks, and replicate measurements where feasible. We provide batch-to-batch comparability data and statistical analysis as part of the deliverable.
Our reports are designed to be suitable for IND/CTA sections. We can bridge to ICH guidelines, provide method validation summaries, and supply raw data upon request. Specific regulatory requirements are discussed during project scoping.
Turnaround time is project-dependent and confirmed at scoping. Routine physicochemical parameters are typically reported within a few weeks, while detailed release kinetics and stability studies require longer timelines. Please contact us for a project-specific estimate.

Scientific Literature

References

Misra R, Hazra S, Saleem S, et al. Drug-loaded polymer-coated silver nanoparticles for lung cancer theranostics. Medical oncology (Northwood, London, England). 2024;41(6):132. View on PubMed
Saorin G, Mauceri M, Caligiuri I, et al. Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer. Cancer letters. 2026;637:218128. View on PubMed
Tóth K, S Nagy K, Güler Z, et al. Characterization of Electrospun Polysuccinimide-Dopamine Conjugates and Effect on Cell Viability and Uptake. Macromolecular bioscience. 2023;23(3):e2200397. View on PubMed
Alfei S, Brullo C, Caviglia D, et al. Preparation and Physicochemical Characterization of Water-Soluble Pyrazole-Based Nanoparticles by Dendrimer Encapsulation of an Insoluble Bioactive Pyrazole Derivative. Nanomaterials (Basel, Switzerland). 2021;11(10). View on PubMed
Ali HM, Attia MH, Mamdouh W, et al. Optimization, thermo-oxidative stability, and biological activities of vitamin E-chitosan-TPP nanoformulations. RSC advances. 2026;16(6):5410-5426. View on PubMed
Lakkakula J, Krause RWM, Barage S, et al. Exploring oral drug delivery: In vitro release and mathematical modeling of hydrophobic drug (Na-L-thyroxine) and its cyclodextrin inclusion complex in chitosan microparticles. International journal of biological macromolecules. 2024;265(Pt 2):131019. View on PubMed

Please kindly note that our products and services are for research use only.